Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?

Gynecologic oncology - 1 Jun 2020

Mills Kathryn A, Joshi Tanvi V, West Lindsay, Kuznicki Michelle, Kent Laura, Hokenstad Alexis N, Cripe James C, Woolfolk Candice, Senter Leigha, Bakkum-Gamez Jamie N, Wenham Robert M, Cohn David E, Bae-Jump Victoria, Thaker Premal H

Abstract excerpt

OBJECTIVES: This study aimed to assess the association between hormone replacement therapy and the incidence of subsequent malignancies in patients who underwent risk-reducing salpingo-oophorectomy and had mutations predisposing them to Müllerian cancers. METHODS: This Institutional Review Board-approved retrospective study was performed at five academic institutions. Women were included if they were age...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genital Neoplasms, Female

Share to Hormone Replacement Therapy

Share to Risk Reduction Behavior

Share to Salpingo-oophorectomy

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 32143914
DOI: 10.1016/j.ygyno.2020.02.033
PMCID: PMC8022862

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?PMID 32143914Read ↗

Patterns of care and outcomes of risk reducing surgery in women with pathogenic variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes.Semantic proximity Read ↗

Retrospective evaluation of risk-reducing salpingo-oophorectomy for BRCA1/2 pathogenic variant carriers among a cohort study in a single institution.Semantic proximity Read ↗

Hereditary Women's Cancer: Management and Risk-Reducing Surgery.Semantic proximity Read ↗

Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Risk-reducing surgery for individuals with cancer-predisposing germline pathogenic variants and no personal cancer history: a review of current UK guidelines.Semantic proximity Read ↗

Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.Semantic proximity Read ↗

Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know.Semantic proximity Read ↗

Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations.Semantic proximity Read ↗

Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.Semantic proximity Read ↗

Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.Semantic proximity Read ↗

Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.Semantic proximity Read ↗

Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.